Peer-reviewed veterinary case report
Blood test helps track lymphoma remission and relapse in dogs
By Alexandrakis, I et al.·Published in Veterinary and comparative oncology·2017·Avacta Animal Health Unit 651, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma undergoing chemotherapy were monitored using a new blood test that checks for specific proteins in their serum. This test, called the canine lymphoma blood test (cLBT), helped veterinarians determine if the dogs were in remission or if the cancer was coming back, even before any physical signs appeared. The results from this blood test were found to be reliable when compared to traditional methods like palpation and cytology. Overall, the cLBT showed promise in helping vets track treatment progress and predict survival times for dogs with lymphoma.
People also search for: dog lymphoma treatment · blood test for dog cancer · signs of lymphoma in dogs
Abstract
A blinded retrospective study was conducted to investigate remission and recurrence of lymphoma in dogs receiving chemotherapy. The objective was to compare clinicians' assessment using palpation and cytology to the results of serum biochemical tests for haptoglobin (Hapt) and C-reactive protein (C-RP). These biochemical test results were combined using a diagnostic algorithm developed using data from 344 individual dogs. This multivariate approach, termed the canine lymphoma blood test (cLBT), was used to follow 57 dogs during and after treatment. cLBT of remission and recurrence compared well with clinicians' assessment and differentiated dogs in remission and those with recurring disease before appearance of lymphadenopathy (P < 0.001). The cLBT demonstrated prognostic potential based on pre-treatment values on dogs with shorter survival times and on those achieving the lowest cLBT score during treatment that showed longer survival times. The test, therefore, demonstrates potential to assist in monitoring treatment of canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25319380/